tricyclic antidepressants, reboxetine or monoamine-oxidase inhibitors (MAOIs) (used for depression)

Also disclosed is a composition comprising reboxetine and a smoking-cessation enhancing agent for use for promoting smoking cessation.

Some antidepressants have been shown to be less effective and less tolerable, such as reboxetine, trazodone and fluvoxamine.

We found that compared to placebo treatment, NRIs (reboxetine in particular) have an effect on improving negative symptoms.

In terms of efficacy, citalopram was more efficacious than other reference compounds like paroxetine or reboxetine, but worse than escitalopram.

It was shown to be better tolerated than tricyclics (when considered as a group) along with amitriptyline, ABT-200, pramipexole and reboxetine.

Citalopram was shown to be significantly less effective than escitalopram in achieving acute response, but more effective than paroxetine and reboxetine.

Noradrenaline reuptake inhibitors (such as reboxetine or atomoxetine) are medicines that might help with the negative symptoms of schizophrenia in particular.

Escitalopram and sertraline showed the best profile of acceptability, leading to significantly fewer discontinuations than did duloxetine, fluvoxamine, paroxetine, reboxetine, and venlafaxine.

The study also showed that nearly three quarters of the data on patients who took part in trials of reboxetine were not published by Pfizer until now.[4]

We found three additional studies that gave us information on the side effects of other SGAs (fluoxetine, escitalopram, duloxetine, and reboxetine), but we cannot compare the drugs directly.

The study also showed that nearly three quarters of the data on patients who took part in trials of reboxetine had not been published by Pfizer.[4]

Corticosteroids, carbenoxolone, liquorice, B2 sympathomimetics in large amounts, and prolonged use of laxatives, reboxetine and amphotericin may increase the risk of developing hypokalaemia.

In terms of early response to treatment (one to four weeks) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine.